265 related articles for article (PubMed ID: 33069804)
21. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
22. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Pessetto ZY; Yan Y; Bessho T; Natarajan A
Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
[TBL] [Abstract][Full Text] [Related]
24. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
25. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
[TBL] [Abstract][Full Text] [Related]
27. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
28. A Novel BRCA1-Associated Protein-1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1-Mediated DNA Repair.
Parrotta R; Okonska A; Ronner M; Weder W; Stahel R; Penengo L; Felley-Bosco E
J Thorac Oncol; 2017 Aug; 12(8):1309-1319. PubMed ID: 28389374
[TBL] [Abstract][Full Text] [Related]
29. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
30. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
31. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
[TBL] [Abstract][Full Text] [Related]
32. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
33. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
[TBL] [Abstract][Full Text] [Related]
34. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
35. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
37. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
[TBL] [Abstract][Full Text] [Related]
38. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
39. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
40. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
